Reviewed by Michael Gill, B. Sc.
14 Thymic Carcinoma Clinical Trials Near Me
Top Hospitals for Thymic Carcinoma Clinical Trials
Image of National Institutes of Health Clinical Center in Maryland.
National Institutes of Health Clinical Center
Bethesda
4Active Trials
5All Time Trials for Thymic Carcinoma
2011First Thymic Carcinoma Trial
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
2Active Trials
3All Time Trials for Thymic Carcinoma
2009First Thymic Carcinoma Trial
Top Cities for Thymic Carcinoma Clinical Trials
Image of Bethesda in Maryland.
Bethesda
6Active Trials
National Institutes of Health Clinical CenterTop Active Site
Thymic Carcinoma Clinical Trials by Phase of Trial
Phase 1 Thymic Carcinoma Clinical Trials
1Active Thymic Carcinoma Clinical Trials
1Number of Unique Treatments
16Number of Active Locations
Most Recent Thymic Carcinoma Clinical Trials
Top Treatments for Thymic Carcinoma Clinical Trials
Treatment Name
Active Thymic Carcinoma Clinical Trials
All Time Trials for Thymic Carcinoma
First Recorded Thymic Carcinoma Trial
Robotic-Assisted Surgery
1
1
2022
PT-112
1
1
2022
KN046
1
2
2020
M7824
1
1
2020
Home-based cardiac rehabilitation
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Thymic Carcinoma
Treatment
Year
Sponsor
Bosutinib
2019
Nagla Abdel Karim

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: October 18th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabé R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20. https://pubmed.ncbi.nlm.nih.gov/343930612 Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7. https://pubmed.ncbi.nlm.nih.gov/183909683 Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003 Jul 1;105(4):546-51. https://pubmed.ncbi.nlm.nih.gov/127124484 Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, Guha U, Wang Y, Szabo E, Meltzer P, Steinberg SM, Trepel JB, Loehrer PJ, Giaccone G. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015 Feb;16(2):177-86. doi: 10.1016/S1470-2045(14)71181-7. Epub 2015 Jan 13. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105. https://pubmed.ncbi.nlm.nih.gov/255926325 Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 2003 Oct;30(5 Suppl 16):105-16. Review. https://pubmed.ncbi.nlm.nih.gov/146130316 Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005 Nov 14;24(50):7455-64. Review. https://pubmed.ncbi.nlm.nih.gov/162882927 He Y, Ramesh A, Gusev Y, Bhuvaneshwar K, Giaccone G. Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell Rep Med. 2021 Sep 3;2(9):100392. doi: 10.1016/j.xcrm.2021.100392. eCollection 2021 Sep 21. https://pubmed.ncbi.nlm.nih.gov/346222298 Lopez-Chavez A, Thomas A, Rajan A, Raffeld M, Morrow B, Kelly R, Carter CA, Guha U, Killian K, Lau CC, Abdullaev Z, Xi L, Pack S, Meltzer PS, Corless CL, Sandler A, Beadling C, Warrick A, Liewehr DJ, Steinberg SM, Berman A, Doyle A, Szabo E, Wang Y, Giaccone G. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9. https://pubmed.ncbi.nlm.nih.gov/256672749 Thomas A, Chen Y, Steinberg SM, Luo J, Pack S, Raffeld M, Abdullaev Z, Alewine C, Rajan A, Giaccone G, Pastan I, Miettinen M, Hassan R. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget. 2015 May 10;6(13):11694-703. https://pubmed.ncbi.nlm.nih.gov/2602866810 Detterbeck FC. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006 Jun;81(6):2328-34. Review. https://pubmed.ncbi.nlm.nih.gov/16731193